Celastrol Alleviates Gamma Irradiation-Induced Damage by Modulating Diverse Inflammatory Mediators.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
06 Feb 2020
Historique:
received: 15 11 2019
revised: 31 01 2020
accepted: 04 02 2020
entrez: 12 2 2020
pubmed: 12 2 2020
medline: 20 11 2020
Statut: epublish

Résumé

The present study aimed to explore the possible radioprotective effects of celastrol and relevant molecular mechanisms in an in vitro cell and in vivo mouse models exposed to gamma radiation. Human keratinocytes (HaCaT) and foreskin fibroblast (BJ) cells were exposed to gamma radiation of 20Gy, followed by treatment with celastrol for 24 h. Cell viability, reactive oxygen species (ROS), nitric oxide (NO) and glutathione (GSH) production, lipid peroxidation, DNA damage, inflammatory cytokine levels, and NF-κB pathway activation were examined. The survival rate, levels of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) in blood, and p65 and phospho-p65 expression were also evaluated in mice after exposure to gamma radiation and celastrol treatment. The gamma irradiation of HaCaT cells induced decreased cell viability, but treatment with celastrol significantly blocked this cytotoxicity. Gamma irradiation also increased free radical production (e.g., ROS and NO), decreased the level of GSH, and enhanced oxidative DNA damage and lipid peroxidation in cells, which were effectively reversed by celastrol treatment. Moreover, inflammatory responses induced by gamma irradiation, as demonstrated by increased levels of IL-6, TNF-α, and IL-1β, were also blocked by celastrol. The increased activity of NF-κB DNA binding following gamma radiation was significantly attenuated after celastrol treatment. In the irradiated mice, treatment with celastrol significantly improved overall survival rate, reduced the excessive inflammatory responses, and decreased NF-κB activity. As a NF-κB pathway blocker and antioxidant, celastrol may represent a promising pharmacological agent with protective effects against gamma irradiation-induced injury.

Identifiants

pubmed: 32041250
pii: ijms21031084
doi: 10.3390/ijms21031084
pmc: PMC7036880
pii:
doi:

Substances chimiques

IL1B protein, human 0
IL6 protein, human 0
Interleukin-1beta 0
Interleukin-6 0
Pentacyclic Triterpenes 0
Radiation-Protective Agents 0
TNF protein, human 0
Triterpenes 0
Tumor Necrosis Factor-alpha 0
Glutathione GAN16C9B8O
celastrol L8GG98663L

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

J Clin Invest. 1991 Aug;88(2):691-5
pubmed: 1864978
Otol Neurotol. 2016 Sep;37(8):e303-8
pubmed: 27518139
Ann Rheum Dis. 2015 Jun;74(6):1078-86
pubmed: 24733191
Curr Vasc Pharmacol. 2017;15(6):503-519
pubmed: 28707601
Apoptosis. 2014 May;19(5):816-28
pubmed: 24375173
Phytother Res. 2011 May;25(5):694-701
pubmed: 21077258
J Photochem Photobiol B. 2016 Aug;161:91-9
pubmed: 27232147
PLoS One. 2013 Nov 04;8(11):e78227
pubmed: 24223778
Blood. 2007 Apr 1;109(7):2727-35
pubmed: 17110449
J Am Soc Hypertens. 2017 Sep;11(9):598-603
pubmed: 28757108
Am J Med Sci. 2015 Nov;350(5):345-51
pubmed: 26473333
J Biomed Sci. 2015 Jul 24;22:61
pubmed: 26205951
PLoS One. 2012;7(4):e35733
pubmed: 22545133
Eur J Clin Invest. 2009 Sep;39(9):819-27
pubmed: 19549173
Biochim Biophys Acta. 2010 Apr;1805(2):167-80
pubmed: 20079806
Free Radic Res. 2015 Apr;49(4):422-39
pubmed: 25812588
Free Radic Res. 2012 Jul;46(7):842-9
pubmed: 22497453
Radiat Res. 2010 Apr;173(4):557-78
pubmed: 20334528
Cancer Lett. 2011 Apr 1;303(1):9-20
pubmed: 21168266
Environ Toxicol Pharmacol. 2010 May;29(3):302-7
pubmed: 21787617
Evid Based Complement Alternat Med. 2011;2011:473953
pubmed: 20008078
PLoS One. 2014 Mar 24;9(3):e93151
pubmed: 24664372
PLoS One. 2014 May 22;9(5):e97599
pubmed: 24854039
PLoS One. 2015 Sep 17;10(9):e0138009
pubmed: 26378927
Int J Radiat Biol. 2017 Apr;93(4):433-439
pubmed: 27813697
Cochrane Database Syst Rev. 2013 Aug 11;(8):CD008568
pubmed: 23934958
Zhonghua Nei Ke Za Zhi. 2013 Jun;52(6):469-73
pubmed: 24059992
Dig Liver Dis. 2015 Jan;47(1):14-9
pubmed: 25445405
Genes (Basel). 2017 Sep 06;8(9):
pubmed: 28878153
Molecules. 2015 May 07;20(5):8242-69
pubmed: 25961164
Health Phys. 2012 Oct;103(4):383-99
pubmed: 23091876
Phytomedicine. 2009 Jan;16(1):47-55
pubmed: 17574826
Evid Based Complement Alternat Med. 2011;2011:175140
pubmed: 19553386
BMC Nephrol. 2015 Dec 04;16:200
pubmed: 26637482
Clin Cancer Res. 2007 Apr 1;13(7):2290-7
pubmed: 17404114
Biochem Pharmacol. 2010 Nov 15;80(10):1553-62
pubmed: 20699088
Pathog Dis. 2016 Aug;74(6):
pubmed: 27405485
Biochim Biophys Acta. 2003 Feb 17;1593(2-3):159-67
pubmed: 12581860
PLoS One. 2013 Apr 26;8(4):e62068
pubmed: 23637966
Life Sci. 2017 Feb 15;171:45-50
pubmed: 28088452
Cell Signal. 2017 Feb;31:105-111
pubmed: 28069440
Environ Toxicol Pharmacol. 2013 Nov;36(3):1197-206
pubmed: 24184571
Exp Toxicol Pathol. 2012 Jan;64(1-2):57-64
pubmed: 20605086
Biomed Pharmacother. 2017 Jul;91:208-219
pubmed: 28458159
Clin Immunol. 2015 Apr;157(2):228-38
pubmed: 25660987
Exp Ther Med. 2018 Aug;16(2):685-694
pubmed: 30116323
Apoptosis. 2011 Oct;16(10):1028-41
pubmed: 21786165
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Mar;34(3):267-71
pubmed: 24758073
Int J Mol Med. 2011 Mar;27(3):441-6
pubmed: 21249311
J Biol Chem. 2006 Jul 21;281(29):19798-808
pubmed: 16682409
Biotechnol Biotechnol Equip. 2014 May 4;28(3):533-539
pubmed: 26019540
J Immunol. 2006 Oct 15;177(8):5612-22
pubmed: 17015749
J Biomed Phys Eng. 2015 Jun 01;5(2):59-66
pubmed: 26157731
Mutat Res. 2011 May 18;722(1):62-8
pubmed: 21440084
Chin Med J (Engl). 2015 Feb 20;128(4):443-9
pubmed: 25673443
J Diabetes Res. 2016;2016:2641248
pubmed: 27057550
Cancer Prev Res (Phila). 2012 Apr;5(4):631-43
pubmed: 22369852
Biochem Pharmacol. 2008 Feb 15;75(4):907-13
pubmed: 18036510
Sci Rep. 2016 Aug 11;6:31577
pubmed: 27509895
Rev Esp Geriatr Gerontol. 2016 Jun;51 Suppl 1:27-33
pubmed: 27719969
Front Oncol. 2015 Jan 20;4:381
pubmed: 25653923
Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1217-25
pubmed: 19545787
Br J Pharmacol. 2011 Nov;164(5):1506-21
pubmed: 21506956
Cell. 2015 May 21;161(5):999-1011
pubmed: 26000480
Arch Toxicol. 2015 May;89(5):711-31
pubmed: 25690730
J Mol Med (Berl). 2014 Mar;92(3):267-76
pubmed: 24233024
Prog Neuropsychopharmacol Biol Psychiatry. 2001 Oct;25(7):1341-57
pubmed: 11513350
Eur J Pharmacol. 2014 Nov 5;742:102-12
pubmed: 25218987
Int J Mol Med. 2010 Apr;25(4):531-6
pubmed: 20198301
Int J Radiat Biol. 2013 Jul;89(7):493-500
pubmed: 23485335
Sci Rep. 2015 Apr 15;5:9700
pubmed: 26814847
Antiviral Res. 2017 Jan;137:49-57
pubmed: 27847245
J Neurochem. 2005 Aug;94(4):995-1004
pubmed: 16092942
Chem Biodivers. 2013 Oct;10(10):1791-803
pubmed: 24130023
J Nucl Med Technol. 2001 Sep;29(3):137-42; quiz 148-50
pubmed: 11564836
Environ Toxicol Pharmacol. 2017 Mar;50:175-182
pubmed: 28189063
Front Pharmacol. 2018 May 03;9:365
pubmed: 29773987
Biochem Biophys Res Commun. 2018 Mar 11;497(3):883-889
pubmed: 29476742
Front Pharmacol. 2017 Jun 16;8:352
pubmed: 28670276
Sci Rep. 2017 Jan 04;7:39874
pubmed: 28051136
J Transl Med. 2013 May 31;11:134
pubmed: 23725518
BMC Complement Altern Med. 2017 Sep 5;17(1):444
pubmed: 28870177
J Biol Chem. 2011 Apr 29;286(17):15138-46
pubmed: 21402700
Biochem Pharmacol. 2016 Dec 1;121:52-66
pubmed: 27664853
Photochem Photobiol. 2012 Nov-Dec;88(6):1385-95
pubmed: 22486439
J Agric Food Chem. 2000 Jan;48(1):88-92
pubmed: 10637057
Cell Mol Biol (Noisy-le-grand). 2012 Mar 23;58 Suppl:OL1646-53
pubmed: 22455981
Oncotarget. 2014 Feb 15;5(3):634-48
pubmed: 24504138
Int J Cancer. 2008 Oct 15;123(8):1733-40
pubmed: 18688862
Mol Med Rep. 2016 Sep;14(3):2799-806
pubmed: 27484716
Radiat Prot Dosimetry. 2017 Apr 1;173(1-3):170-176
pubmed: 27886996
Semin Cancer Biol. 2016 Oct;40-41:35-47
pubmed: 27038646
J Ethnopharmacol. 2014 Jul 3;154(3):624-34
pubmed: 24814319
Free Radic Res. 2019 Mar;53(3):324-334
pubmed: 30773944
Biochem Biophys Res Commun. 2004 Sep 24;322(3):778-86
pubmed: 15336532

Auteurs

Hong Wang (H)

Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore.
Singapore Nuclear Research and Safety Initiative, National University of Singapore, Singapore 138602, Singapore.

Kwang Seok Ahn (KS)

College of Korean Medicine, Kyung Hee University, #47, Kyungheedae-gil, Dongdaemoon-gu, Seoul 130-701, Korea.

Sulaiman Ali Alharbi (SA)

Department of Botany and Microbiology, College of Science, King Saud University, Riyadh-11451, Saudi Arabia.

Omar Hm Shair (OH)

Department of Botany and Microbiology, College of Science, King Saud University, Riyadh-11451, Saudi Arabia.

Frank Arfuso (F)

Stem Cell and Cancer Biology Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6009, Australia.

Gautam Sethi (G)

Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore.

Arunachalam Chinnathambi (A)

Department of Botany and Microbiology, College of Science, King Saud University, Riyadh-11451, Saudi Arabia.

Feng Ru Tang (FR)

Singapore Nuclear Research and Safety Initiative, National University of Singapore, Singapore 138602, Singapore.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH